Portal de Periódicos da CAPES

A Comparative Study on Ceftazidime and Cefoperazone in the Treatment of Urinary Tract Infections in Double Blind Manner

1984; Volume: 58; Issue: 9 Linguagem: Inglês

10.11150/kansenshogakuzasshi1970.58.862

1884-569X

Nobuo Kawamura, T Hihara, Hideshi Miyakita, Toshifumi Kawashima, Yoshihiro Nagata, Yoji KATSUOKA, Keishi Okada, Hidechika Kinoshita, Kazuo Matsushita, Masaaki OHKOSHI, Yoshiaki Kumamoto, Takaoki Hirose, Chosho Enatsu, Seigi Tsuchida, Hitoshi Takada, Hiromitsu NOTO, Shigeki Matsuo, Hironori Kaneko, Takashi Tominaga, Hiroichi Kishi, Tadao Niijima, Tadaichi Kitamura, Yoji Nishimura, Isao Saito, Michio Asano, Junji Yuge, Toyokazu Saito, Toyohei Machida, Shoichi Onodera, Hiroo Suzuki, Ichiro Nagakubo, Kiyotaka Hoshinaga, Motoharu Matsui, Katsuo Takanashi, Yasuhide Yamamoto, Keizô Suzuki, Haruo Hisazumi, Mitsuo Ohkawa, Shoji Hirano, Ikuo Mikawa, Yorio Naide, Tamio Fujita, Tadashi Ogawa, Satoshi Hirabayashi, Masanori Yanaoka, Norihiko Okishio, K Ishiguro, Ryuichiro Moriguchi, Katsutoshi Kobayashi, Yoshihito Ban, Yukimichi Kawada, Tsuneo Nishiura, Tatsuo Doi, S. Ishiyama, O Setsuda, Kazutoshi Isogai, Toshimi Takeuchi, Kanhin Tei, Akira ZAITSU, Osamu Yoshida, Yoshito Higashi, J Ishigami, S Kamidono, Soichi Arakawa, Masuyoshi Harada, Toru OHBE, H Yasuno, Hideo OHSHIMA, Shuso Den, Nobuo Kataoka, Hiroshi Okudaira, Gaku Kawabata, Osamu Tomioka, Hiroshi Yamasaki, Hiroyuki Ohmori, Hiromi Kumon, Atsushi Kondo, Katsuichi Nanba, Tsuyoshi Shiraga, Yasuhiro Katayama, Teruaki Akaeda, Hitoshi Takamoto, Hideo Kamata, Takashi Kume, Hiromi Nihira, M Kodama, Yoshikatsu Kobukata, Hiroyuki Moriyama, Kazuo Kurokawa, Nobuo Fujimura, Kenji Yuasa, Shinichiro Kitada, Kazuhiro Yoshimine, Kohei Senoh, Kosaku Eto, Shogo Ueda, Joichi Kumazawa, Seiichi Nakamuta, Fukuzo Matsuya, Eiji SHIMOMAE, Yoshitada Ohi, Takashi Kawabata, Toshihiro Goto, Motoshi Kawahara, Setsuo Asechi, Nichiro Sakamoto, Shigekazu Nagata, Shizuo Yagi, Michio Obata, Tsuyoshi Shimada, Kazue Ueno,

Reproductive tract infections research

The clinical efficacy, safety and usefulness of Ceftazidime (CAZ) in complicated urinary tract infectionswere evaluated in comparison with Cefoperazone (CPZ) in double blind manner, and thefollowing results were obtained.CAZ 1g/day, CAZ 2g/day or CPZ 2g/day was administered by intravenous drip infusion twice dailyfor 5 days.In the overall clinical efficacy evaluation according to the criteria proposed by UTI committee in Japan, the efficacy rates were 63% in 125 cases in the CAZ 1g/day group, 68% in 119 cases in the CAZ 2g/day group and 52% in 119 cases in the CPZ 2g/day group, with no significant difference among thethree groups (H-test). When 2 groups were compared (X2-test), however, the CAZ 2g/day was shown tobe superior over CPZ .2 g/day with statistically significant difference. As to the clinical efficacy classifiedby the type of infections, CAZ (both 1g/day and 2g/day) was more effective than CPZ (2g/day) withstatistically significant difference in polymicrobial infections. It was noteworthy that in the G-5 group, CAZ 1g/day was significantly better than CPZ 2g/day.The elimination rates in bacteriuria were 53%, 52% and 45%, in CAZ 1g/day, CAZ 2g/day and CPZ 2g/day, and the clearance rates in pyuria were 35%, 33% and 23%, respectively, with no significantdifference among the three groups. In the clearance + decrease rates, however, the CAZ 1g/day and CAZ 2g/day groups showed better results than CPZ 2g/day group with statistically significantdifference.In the bacteriological response, CAZ 1g/day and 2g/day showed statistically higher eradicationrates than CPZ 2g/day in the total number of organisms and gram negative bacteria, but in gram positivebacteria, CPZ 2g/day showed higher eradication rates than CAZ 1g/day with statistically significantdifference. When reviewed for each organism, CAZ 1g/day and 2g/day showed higher eradication ratesthan CPZ 2g/day in S. marcescens with statistically significant difference; however, there was nosignificant difference among the three groups in the other organisms. Number of organisms whichemerged after treatment was large with S. faecalis and Yeast-like organisms in all the three groups. No severe adverse reaction or abnormal laboratory finding was observed in any group; therefore, there was no significant difference among the three groups. From the above results, CAZ was judged to be an antibiotic with clinical usefulness equal to, or evenhigher than that of CPZ.